Entry into a Material Definitive Agreement
Show detailsHide details
1.01 Entry into a Material Definitive Agreement · 8.01 Other Events · 9.01 Financial Statements and Exhibits
Bridgebio Pharma, Inc.
A biopharmaceutical company developing medicines for genetic diseases, BridgeBio's approved products include Attruby for a heart condition called ATTR-CM and Truseltiq for bile-duct cancer. Founded in 2015, its name reflects a mission of 'bridging' genetic research to patients, and it runs a hub-and-spoke model where small teams advance each drug. Its experimental oral therapy for achondroplasia was the first-ever treatment for children with the condition to earn the FDA's Breakthrough Therapy designation.
1.01 Entry into a Material Definitive Agreement · 8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 3.02 Unregistered Sales of Equity Securities · 3.03 Material Modification to Rights of Security Holders · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 9.01 Financial Statements and Exhibits